Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.20.1
Significant Accounting Policies (Details Narrative) - USD ($)
12 Months Ended
Jun. 04, 2018
Dec. 31, 2019
Dec. 31, 2018
Jan. 02, 2019
Change in fair value of derivative liabilities   $ 191,656  
Cumulative dividend percentage   8.00%    
Deferred revenue related to contract   $ 33,000 33,000  
FDIC insured amount   250,000    
Uninsured cash balance   1,867,286 2,490,645  
Right of usee assets and operating lease liabilities   $ 826,397  
ASC Topic 842 [Member]        
Right of usee assets and operating lease liabilities       $ 1,099,400
Revenue [Member] | LeMaitre Vascular, Inc [Member]        
Concentration risk percentage   100.00% 62.00%  
Revenue [Member] | Hancock Jaffe Laboratory Aesthetics, Inc [Member]        
Concentration risk percentage     38.00%  
Initial Public Offering [Member]        
Fair value of derivative liabilities reclassified to additional paid in capital $ 3,594,002      
Minimum [Member]        
Estimated useful life of property and equipment   5 years    
Maximum [Member]        
Estimated useful life of property and equipment   7 years    
Hancock Jaffe Laboratory Aesthetics, Inc [Member]        
Ownership percentage   28.00%    
Investments   $ 0